Skip to main content

Colour-enhanced scanning electron micrograph of a cannabis plant.

TED M. KINSMAN/The Globe and Mail

From the outside, MediPharm Labs’ production facility looks like another non-descript warehouse in an industrial park. The interior of the facility in Barrie, Ont., however, is a beehive of employees in white lab coats and polypropylene hair nets working inside brightly lit glass cubes. They hover over high-tech machinery with pedals and metal cylinders that turn cannabis flower into concentrate using a technique known as supercritical carbon dioxide extraction. It’s not unlike making espresso coffee, with a few important distinctions. Some of these custom-made machines cost $1 million, and a single litre of the cannabis resin is worth as much as $100,000.

MediPharm Labs Corp. is not as widely known as market leaders like Canopy Growth, Aurora Cannabis or Tilray—but it’s catching up fast. It’s been overlooked so far as a niche player without a multibillion dollar valuation. Unlike other cannabis companies, the firm isn’t trying to manage an entire supply chain from farming to processing to marketing. Instead, as the name suggests, it’s a pharmaceutical maker focused on doing one thing really well. MediPharm buys high-quality cannabis flowers from more than 20 carefully vetted suppliers, then converts them for use in recreational and medical products. “We’ve adopted a Swiss perspective. We work with many suppliers and sell to many customers,” says Pat McCutcheon, co-founder and CEO of MediPharm Labs. In other words, they’re neutral—not passive. On the day of this interview, McCutcheon wears a dark suit with a tartan pattern and a navy tie with tiny skulls and bones, hinting at a rebellious streak.

The next chapter of pot legalization, dubbed Cannabis 2.0, will introduce new products—such as edibles, beverages, vape pens and creams—by mid-December of this year, all of which will be fuelled by the kind of cannabinoid-based extracts produced by MediPharm Labs. In effect, the company aims to be to cannabis what Frank Stronach's Magna International is to the global car business—a strategic supplier of critical components that go into nearly everything its industry makes. That position in the middle of the supply chain has allowed MediPharm Labs to emerge as the biggest contract manufacturer of cannabis oil not only in Canada, but quite possibly North America and the world. Under the deal signed last month with Mississauga's TerrAscend, a seller of prescription cannabinoids, McCutcheon's firm will supply distillate worth $27 million over two years, with a potential to balloon to $192 million over three years. An agreement with the Cronos Group to supply high-quality cannabis concentrate is worth $30 million over 18 months, with the potential to double. Strategic partnerships like these have turned MediPharm Labs into the most profitable cannabis company in the country and the fourth-biggest by revenue after Canopy, Aurora and Aphria.

Story continues below advertisement

MediPharm’s upward climb through industry ranks comes as the hype surrounding the first phase of cannabis legalization in Canada has been dampened by a few sobering realities. Virtually everyone in the industry is losing money, the threat of writedowns looms large, and the recent health controversy over vape products has caused the valuation of cannabis stocks to take a significant hit. But MediPharm reported net income of $4.1 million on revenue of $31.5 million in its latest quarter. Maybe its low-key, focused approach is exactly what the industry needs. “We don’t sell mystery,” explains McCutcheon, 39, noting his company’s market cap is $442.8 million. The company recently switched its public listing to the TSX from the more speculative TSX Venture Exchange. “We sell fundamentals and execution.”


McCutcheon worked in the medical industry for 15 years before launching his cannabis firm in 2015 with company president Keith Strachan. His last stint was at Johnson & Johnson, where he led a hospital division focused on kidney and mental health drugs. He’s the company strategist, keeping an eye on the global picture. While producing resins and distillates for edibles and beverages seems lucrative today, increased competition will likely squeeze margins. McCutcheon’s plan is to shift the company’s focus to producing 99.9% pure ingredients for the health care market, helping to create drugs to combat everything from chronic pain to cancer.

By contrast Strachan, 34, is the regulatory brains. His background in hospital procurement and government contracts enabled his firm to land the first-ever cannabis oil production licence in Canada granted to a non-cultivator. McCutcheon and Strachan met at the Royal Victoria Regional Health Centre in Barrie, and soon recognized they had similar ambitions. Their shared pharma experience has created opportunities, including participation in a ground-breaking clinical trial for developing a non-addictive medication for opioid addiction at New York’s Mount Sinai Hospital. “I like MediPharm’s management team because they come from a pharmaceutical background,” says analyst Scott Fortune with Roth Capital Partners in Newport Beach, Calif. “If you start from a high scientific level, it’s easy to transfer that knowledge to everyday consumer products.”

Colour-enhanced scanning electron micrograph of a cannabis plant leaf.

TED M. KINSMAN/The Globe and Mail

And a wave of consumer products is on its way. The next wave of legalization will bring branded offerings with high margins: cannabis-infused edibles like cookies and gummy worms, beverages, topical creams and vape dispensers. Conservative estimates place the value of the Canadian cannabis industry at about $6 billion by 2021 while these new products are expected to be worth about $2.7 billion, according to a recent Deloitte study. And they might also help address some of the challenges that have bedevilled the industry so far.

The sale of legal cannabis products in this country has so far been stymied by myriad factors, including the slow rollout of dispensaries in most provinces. This, in turn, has fuelled an unregulated online market for cannabis products that largely escapes enforcement. Meanwhile, licensed retailers are carefully scrutinized for compliance. “It's hard for the regulated market to compete, with all the restrictions on packaging and advertising, when the black market is allowed to operate outside the law,” says Louis Barre, principal at Ottawa-based consultancy Cannab Intel. The situation is compounded by the premium paid by Canadians for legal cannabis bud—as much as 80% above unregulated and untaxed prices. “A premium of no more than 20% is needed for the legal market to thrive,” says John Kagia, chief knowledge officer at New Frontier Data in Washington, D.C.

The illegal market will have a tough time competing with the new offerings coming with Cannabis 2.0. “The next generation of products will be more effective at combating the black market because quality will be much higher,” says McCutcheon. Consumers have criticized the quality of the legal bud now available at licensed dispensaries, leading them to see advantages to partaking in unlicensed options. But it’s unlikely that illegal operators will be able to make the technological investment to produce these new products. MediPharm Labs’ equipment was designed by biotech specialists, including GMP Engineering of Newmarket, Ont., whose clients include Pfizer, GlaxoSmithKline and Bayer. MediPharm has spent $30 million on its Barrie facility so far, and plans to spend a further $15 million to $20 million over the next 18 months.

In addition, every batch of legal cannabis oil made in this country must be analyzed by third-party labs that check for undesirable compounds including heavy metals, pesticides and residual solvents. A company must also prove that its emulsification or mixing process is sufficiently robust to distribute active ingredients evenly in, say, an edible or beverage before a product is greenlit by Health Canada.

Story continues below advertisement

In contrast, illegally made products have little or no quality control. Open-tank mixing by hand results in poor ingredient dispersal, and the result is product that fails to deliver consistency and predictability of experience. A much bigger problem is that the black market often uses untested additives and cutting agents. There are indications that the latest outbreak of pulmonary disease linked to vaping in the U.S. is linked to vitamin E acetate, commonly used to enrich the colour and viscosity of low-quality oils. It's sometimes safe when used in topical skin creams, but toxic when inhaled.

In American jurisdictions in which recreational cannabis products are legal, there is no shortage of stories about people either getting too high—or not getting high at all—from different products that report having the same dose. Analysts blame the fact that U.S. cannabis laws are made at the state rather than federal level, making standardization difficult to achieve. “Canada’s rollout of Cannabis 2.0 won’t be entirely smooth,” says Fortune. “But it will be safe, and it’s unlikely to be plagued by many of the issues we’ve seen in U.S. jurisdictions.”


It’s after 5 p.m. and McCutcheon is sitting in his new office on the 42nd floor in Toronto’s financial district, winding down from another juggernaut day. It began with a 90-kilometre drive south down the highway from Barrie for meetings on Bay Street. The schedule also included discussions with a potential joint-venture partner and face time with PowerOne, one of the company’s private equity investors. Over five years, McCutcheon has watched Canada’s legal cannabis industry grow, but there’s one thing that still surprises him. “It’s the influence that capital markets have over the fundamental operations of companies,” he says. “The pressure and anxiety around raising exorbitant sums of money to build facilities even before you have a licence is huge.”

TED M. KINSMAN/The Globe and Mail

MediPharm Labs has been lucky in that respect. Its latest round of financing in June raised $75 million in a bought deal underwritten by a syndicate led by Scotia Capital, GMP Securities and BMO Nesbitt Burns. That same month, MediPharm Labs signed a manufacturing agreement with Toronto-based Ace Valley to potentially produce at least two million cannabis-oil vape pens over the next three years. That number could increase significantly depending on the direction the market takes.

Meanwhile, to press ahead with McCutcheon’s plan to become a global supplier of specialty medicinal ingredients, MediPharm Labs will need an international footprint. The first step is opening an extraction facility in Australia later this year. “We’re going to look a lot different two years from now, I guarantee it,” says McCutcheon. Estimates on the size of the global medical market for cannabis products vary, but at the high end it could be worth as much as US$148 billion by 2026. Australia will be the launch pad into Thailand and South Korea for the company. Those countries are ideal partners for MediPharm Labs because they’re most interested in importing finished products. The Canadian company is also working to obtain a GMP (good manufacturing practice) certification for export into the EU and Latin America. “Five years ago only four countries around the world were open to cannabis-derived medicines,” says Kagia at New Frontier Data. “Today that number is more like 60 and counting.”

Being able to respond to market trends is important as consumers refine their tastes. In the U.S. there’s been a dramatic shift to infused products in recent years. Edibles and beverages have played a role, but vaping is the single biggest factor, accounting for 30% of a US$13.6-billion market for cannabis. “We can scale up for customer orders and build needed capacity with speed,” says Strachan. That ability to execute with precision has been a big reason behind his company’s rise into the front ranks of the cannabis industry. Staying there will be the challenge.

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...